Lyell Immunopharma Inc (LYEL) — Financial Flexibility Index
Lyell Immunopharma Inc (LYEL) has a Financial Flexibility Index of -0.35x as of December 2025. Free cash flow of $-31.88 Million (operating CF $-32.25 Million minus capex $366.00K) represents 0% of total liabilities ($91.85 Million). Check LYEL capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Lyell Immunopharma Inc Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for Lyell Immunopharma Inc across 7 annual periods. For the full cash flow conversion analysis, see LYEL cash flow conversion.
Annual Financial Flexibility Index for Lyell Immunopharma Inc (2019–2025)
Year-by-year free cash flow to debt coverage for Lyell Immunopharma Inc. Explore Lyell Immunopharma Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -1.62x | $-149.24 Million | $-150.02 Million | $91.85 Million | ▼ -8.4% |
| 2024 | -1.50x | $-161.93 Million | $-162.39 Million | $108.03 Million | ▲ +11.5% |
| 2023 | -1.69x | $-161.01 Million | $-163.69 Million | $95.08 Million | ▼ -21.6% |
| 2022 | -1.39x | $-145.28 Million | $-169.56 Million | $104.31 Million | ▼ -353.1% |
| 2021 | -0.31x | $-60.74 Million | $-126.25 Million | $197.62 Million | ▲ +46.7% |
| 2020 | -0.58x | $-109.39 Million | $-160.87 Million | $189.84 Million | ▼ -253.2% |
| 2019 | 0.38x | $55.52 Million | $39.47 Million | $147.58 Million | — |